Agendia Is A Precision Oncology Company Focused On Genomic Profilingparticularly For Early Stage Breast Cancerfounded In 2003 By Leading Researchers From The Netherlandsagendia Has Established Itself As A Global Leader In Innovative Genomic Technology And Diagnostic Teststhe Company Is Headquartered In Irvinecaliforniaand Maintains Strong Connections With European Research Institutions Agendia Offers Two Primary Genomic Testsmammaprint And Blueprintmammaprint Assesses The Risk Of Cancer Recurrence In Early Stage Breast Cancer Patientsaiding In Treatment Decisionsblueprint Provides Insights Into The Biological Characteristics Of Tumorshelping To Identify The Subtype Of Breast Cancer And Further Assist In Treatment Planningthese Tests Support Personalized Medicine Approaches For Breast Cancer Patients The Company Is Committed To Improving Patient Outcomes And Quality Of Life Through Advancements In Genomic Technologyagendia Actively Engages In Research And Developmentholding Multiple Patents And Emphasizing Innovation In Precision Oncology
